Stem Cell Therapy in Muscular Dystrophy

Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02241928

Enrollment

Registered

2014-09-16

Start date

2009-01-31

Completion date

2019-05-31

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscular Dystrophy

Keywords

Muscular Dystrophy, Autologous Mononuclear cell therapy, Stem Cell

Brief summary

The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.

Interventions

BIOLOGICALStem Cell

Intrathecal Autologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to 60 Years

Healthy volunteers

Inclusion criteria

* age group of 6 months and above * muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion criteria

* presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Manual Muscle Testing	1 year

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026